MedTrace Logo

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

NCT05227690 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2025-09-17

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.

Conditions

Interventions

DRUG

Placebo

Matching placebo, oral (tablet), once per day for 6 weeks

DRUG

Emraclidine 10 mg

Emraclidine 10 mg, oral (tablet), once per day for 6 weeks

DRUG

Emraclidine 30 mg

Emraclidine 30 mg, oral (tablet), once per day for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2024-08-23
Completion
2024-08-26
FDA Drug
Yes

Countries

  • United States
  • Bulgaria

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227690 on ClinicalTrials.gov